» Articles » PMID: 39300933

Benefit of Implantable Cardioverter Defibrillator Use in Japanese Patients Based on Modified MADIT-ICD Benefit Score

Abstract

Aims: The MADIT-ICD benefit score is used to stratify the risk of life-threatening arrhythmia and non-arrhythmic mortality. We sought to develop an implantable cardioverter defibrillator (ICD) benefit-prediction score for Japanese patients with ICDs.

Methods: Patients who underwent ICD implantation as primary prophylaxis were retrospectively enrolled. Based on their MADIT-ICD benefit scores, we developed a modified MADIT-ICD benefit score adapted to the Japanese population. The primary endpoints were appropriate ICD therapy and all-cause death without appropriate ICD therapy (non-arrhythmic death). We used the Fine and Gray multivariate model and Cox proportional hazard regression to identify factors for adjusting the MADIT-ICD benefit-risk score specifically for the Japanese population. The scoring points for the original MADIT-ICD benefit score were adjusted to optimal points based on the multivariate analysis results in the population.

Results: The study enrolled 167 patients [age, 61.9 ± 12.3 years; male individuals, 138 (82.6%); cardiac resynchronization therapy, 73 (43.7%); ischaemic cardiomyopathy, 53 (31.7%)]. Fourteen patients received anti-tachycardia pacing (ATP) therapy, and 23 received shock therapy as the initial appropriate ICD therapy. Non-arrhythmic deaths occurred in 37 patients. The original MADIT-ICD benefit score could not stratify non-arrhythmic mortality in the Japanese population. The patients were reclassified into three groups according to the modified MADIT-ICD benefit score. The modified MADIT-ICD benefit score could effectively stratify the incidence of appropriate ICD therapy and non-arrhythmic mortality. In the highest-benefit group, the 10 year cumulative rates of appropriate ICD therapy and non-arrhythmic mortality were 56.8% and 12.9%, respectively (P < 0.01). In the intermediate-benefit group, these rates were 20.2% and 40.2% (P = 0.01). In the lowest-benefit group, the incidence of non-arrhythmic deaths was 68.1%, and no patient received appropriate ICD therapy.

Conclusions: The modified MADIT-ICD benefit score may be useful for stratifying ICD candidates in the Japanese population.

Citing Articles

Benefit of implantable cardioverter defibrillator use in Japanese patients based on modified MADIT-ICD benefit score.

Chiba T, Kondo Y, Shiko Y, Nakano M, Takatsugu K, Nakano M ESC Heart Fail. 2024; 12(1):369-378.

PMID: 39300933 PMC: 11769601. DOI: 10.1002/ehf2.15081.

References
1.
Noda T, Kurita T, Nitta T, Chiba Y, Furushima H, Matsumoto N . Significant impact of electrical storm on mortality in patients with structural heart disease and an implantable cardiac defibrillator. Int J Cardiol. 2018; 255:85-91. DOI: 10.1016/j.ijcard.2017.11.077. View

2.
MOSS A, Hall W, Cannom D, Daubert J, Higgins S, Klein H . Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335(26):1933-40. DOI: 10.1056/NEJM199612263352601. View

3.
Desai A, Fang J, Maisel W, Baughman K . Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004; 292(23):2874-9. DOI: 10.1001/jama.292.23.2874. View

4.
Kondo Y, Noda T, Takanashi Y, Sasaki S, Sato Y, Nitta T . Two-Year Outcomes of Primary Prophylactic Use of Defibrillators for Ischemic and Non-Ischemic Cardiomyopathy - Propensity Score-Matched Analysis From the Nippon Storm Study. Circ J. 2023; 88(7):1107-1114. DOI: 10.1253/circj.CJ-23-0613. View

5.
Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K . JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. Circ J. 2021; 85(7):1104-1244. DOI: 10.1253/circj.CJ-20-0637. View